|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Mental Health (NIMH) |
|---|---|
| Information provided by: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00044616 |
Purpose
This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®), lithium, the combination of these two medications, and placebo in treating and preventing recurrent depressive episodes in people with bipolar type II disorder.
| Condition | Intervention | Phase |
|---|---|---|
|
Bipolar Disorder Depression |
Drug: Fluoxetine Drug: Lithium |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Relapse Prevention of Bipolar Type-II Disorder |
| Estimated Enrollment: | 180 |
| Study Start Date: | February 2001 |
| Study Completion Date: | January 2007 |
| Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
Bipolar II (BP II) disorder is characterized by a high recurrence of major depressive episodes (MDE), and it is associated with substantial illness and deaths. Unfortunately, relatively little attention has been given to treatment of BP II. Concern that patients may switch from depressed to manic states during treatment of MDE has impeded the development of effective treatments for BP II MDE.
BP II MDE patients are treated initially with fluoxetine for 10 weeks. Patients who recover from MDE are then randomized to receive a relapse-prevention treatment of fluoxetine, lithium, a combination of fluoxetine and lithium, or placebo for 1 year. Patients undergo clinical and laboratory evaluations, including physical examinations, bloodwork, thyroid function tests, electrocardiogram (ECG), urinalysis, and HAM-D, YMR, CGI-S, CGI-I, and adverse events scales.
For information on a related study, please follow this link:
http://clinicaltrials.gov/show/NCT00602537
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Bipolar II Depression
Contacts and Locations More Information
| Study ID Numbers: | R01 MH060353-01, DSIR 83-ATP |
| Study First Received: | September 3, 2002 |
| Last Updated: | February 19, 2009 |
| ClinicalTrials.gov Identifier: | NCT00044616 History of Changes |
| Health Authority: | United States: Federal Government |
|
Neurotransmitter Agents Depression Bipolar Disorder Psychotropic Drugs Lithium Carbonate Depressive Disorder Serotonin Uptake Inhibitors Serotonin Behavioral Symptoms |
Fluoxetine Affective Disorders, Psychotic Mental Disorders Mood Disorders Psychotic Disorders Antidepressive Agents, Second-Generation Antidepressive Agents Lithium |
|
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Depression Disease Molecular Mechanisms of Pharmacological Action Bipolar Disorder Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors Pharmacologic Actions Behavioral Symptoms |
Fluoxetine Affective Disorders, Psychotic Serotonin Agents Pathologic Processes Mental Disorders Therapeutic Uses Mood Disorders Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |
